Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treating to target with statins.

P J Barter1

  • 1Department of Medicine, University of Adelaide and Division of Cardiovascular Services, Royal Adelaide Hospital, Adelaide, South Australia. pbarter@medicine.adelaide.edu.au

Atherosclerosis. Supplements
|April 5, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plaque stabilizing effects of apolipoprotein A-IV.

Atherosclerosis·2016
Same author

Assessment of cardiometabolic risk and prevalence of meeting treatment guidelines among patients with type 2 diabetes stratified according to their use of insulin and/or other diabetic medications: results from INSPIRE ME IAA.

Diabetes, obesity & metabolism·2013
Same author

Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2012
Same author

Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes.

Diabetologia·2010
Same author

Role of 3beta-hydroxysteroid-delta 24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells.

Arteriosclerosis, thrombosis, and vascular biology·2009
Same author

Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I.

Diabetologia·2008
Same journal

'Diet and lifestyle' in the management of dyslipidaemia and prevention of CVD - Understanding the level of knowledge and interest of European Atherosclerosis Society members.

Atherosclerosis. Supplements·2021
Same journal

Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool.

Atherosclerosis. Supplements·2021
Same journal

Lipid Clinics Network. Rationale and design of the EAS global project.

Atherosclerosis. Supplements·2021
Same journal

Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives.

Atherosclerosis. Supplements·2021
Same journal

Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project.

Atherosclerosis. Supplements·2021
Same journal

Prevalence and relationship between metabolic syndrome and risk of cardiovascular disease: Evidence from two population-based studies.

Atherosclerosis. Supplements·2021
See all related articles

Cholesterol-lowering therapy, particularly statins like atorvastatin, effectively reduces coronary event risk. Many high-risk patients still don't reach recommended cholesterol targets despite available treatments.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Large trials confirm cholesterol-lowering therapy reduces coronary events.
  • Consensus exists to lower plasma total and LDL-C to target levels for reduced CHD risk.
  • A significant number of high-risk patients are undertreated or do not reach lipid targets.

Purpose of the Study:

  • To evaluate if current lipid-lowering drugs can achieve recommended cholesterol targets.
  • To assess the effectiveness of statins in reaching target lipid levels in at-risk patients.

Main Methods:

  • Review of treatment-to-target studies.
  • Analysis of data from clinical trials on lipid-lowering therapies.

Main Results:

Related Experiment Videos

  • Statins effectively achieve recommended lipid target levels in most at-risk patients.
  • Atorvastatin is particularly effective in helping patients reach total cholesterol targets.
  • Despite proven efficacy, many patients remain below therapeutic goals.

    • Conclusions:

    • Current lipid-lowering therapies, especially statins, are capable of achieving target cholesterol levels.
    • Further efforts are needed to ensure all high-risk patients attain recommended lipid targets for optimal cardiovascular protection.